Oncolytics Biotech ONCY
NASDAQ ONCY
$0.51 +0.01 (+2.57%)
At close: Oct 21, 2026 · 4:00 PM EDT

Oncolytics Biotech (ONCY) EBITDA Margin (2010 - 2025)

Updated

Oncolytics Biotech (ONCY) posted EBITDA Margin of -760.93% for Q2 2017, down 1135.54 percentage points from 374.60% a year earlier.

Analysis

Oncolytics Biotech (ONCY) EBITDA Margin (2010 - 2025) Analysis & Trends

For the trailing twelve months through Jun 30, 2017, EBITDA Margin at Oncolytics Biotech was -802.07%, down 831.67 percentage points year-over-year; for FY2009, it came in at -5140.04%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 Oncolytics Biotech 60.94 Mn 32.05 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -14,583.00%
Sep 30, 2024 -3,625.29%
Sep 30, 2021 -18,615.22%
Dec 31, 2020 -98.46%
Jun 30, 2018 18,041.41%
Mar 31, 2018 17,542.96%
Jun 30, 2017 -760.93%
Jun 30, 2016 374.60%
Jun 30, 2010 -111.59%
API Access

Oncolytics Biotech EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ONCY&period=max&api_key=YOUR_API_KEY